Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience.
Sakshi MittalG S R S N K NaiduSaket JhaManish RathiRitambhra NadaRanjana W MinzKusum SharmaVarun DhirSanjay JainAman SharmaPublished in: Clinical rheumatology (2020)
• Remission was achieved in 60% of GPA patients who received similar biologic of rituximab as remission induction therapy. • Relapse rate during maintenance phase was 12% with similar biologic of rituximab. Serious infections and mortality with similar biologic of rituximab were comparable with that reported previously in AAV trials.
Keyphrases
- rheumatoid arthritis
- diffuse large b cell lymphoma
- disease activity
- chronic lymphocytic leukemia
- hodgkin lymphoma
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- peritoneal dialysis
- cardiovascular events
- ulcerative colitis
- type diabetes
- risk factors
- systemic lupus erythematosus
- free survival
- cell therapy
- smoking cessation